

# (Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

#### UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

#### 1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2020. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2020.

The audited financial statements of the Group for the year ended 31 December 2020 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2020.

#### 2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2020 were no subject to any qualification.

#### 3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

#### 4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect on the current quarter results.

#### 5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

#### 6. DIVIDENDS PAID

There was no dividend paid during the current quarter under review.



# (Company No: 200301016113 (618533-M)) (Incorporated in Malaysia)

# THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

UNAUDITED NOTES TO FINANCIAL STATEMENTS

TRADE AND OTHER RECEIVABLES

	As at 30-Sep-21 RM ('000)	As at 31-Dec-20 RM ('000)
Trade Receivables	` ,	` ,
Third parties	43,063	23,190
Allowance for impairment loss	(8,874)	(6,090)
	34,189	17,100
Other Receivables		
Third and Related parties	11,120	4,276
Allowance for impairment loss		(356)
	11,120	3,920
Deposits and Prepayments	2,960	460
	48,269	21,480

#### a) Trade Receivables

7.

The Group's normal trade credit term ranges from 30 to 90 days (2020: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	As at 30-Sep-21 RM ('000)	As at 31-Dec-20 RM ('000)
Not past due	17,962	7,598
Past due:		
- Less than 30 days	10,578	1,779
- 31 to 60 days	3,739	949
- 61 to 90 days	1,432	513
- More than 90 days	9,352	12,351
	43,063	23,190
Less: Loss allowance		
<ul> <li>Collectively impaired</li> </ul>	(3,721)	(937)
<ul> <li>Individually impaired</li> </ul>	(5,153)	(5,153)
Trade Receivable net	34,189	17,100



(Company No: 200301016113 (618533-M)) (Incorporated in Malaysia)

# THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

# UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

#### 8. SEGMENTAL INFORMATION

**Healthcare**: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which is for home and center-based treatments, serving both the domestic and export markets. The renal dialysis business was disposed of on 3 May 2021.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for the current quarter are as follow:

Revenue	Individual Quarter Ended		Cumulative Q	uarter Ended
	30-Sep-21	30-Sep-20	<b>30-Sep-21</b>	30-Sep-20
<b>Segment</b>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	43,423	16,033	76,476	93,991
Corporate	62	488	648	1,485
Elimination	(62)	(2,055)	(682)	(20,963)
Total	43,423	14,466	76,442	74,513
PBT/(LBT) result				
<b>Segment</b>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	3,612	(5,332)	10,937	(2,232)
Corporate	(100)	105	(988)	(509)
Elimination		-	-	-
Total	3,512	(5,227)	9,949	(2,741)

#### 9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.



# (Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

#### UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### 10. SIGNIFICANT EVENTS

Significant and subsequent event announced from the previous quarter are as follow:

The Company announced that the completion of the Proposed Disposal of the entire equity of Lucenxia (M) Sdn. Bhd. ("Lucenxia") took place on 3 May 2021 as all the Conditions Precedent in the Share Sale Agreement ("SSA") have been fulfilled and the SSA has become unconditional. Approval has been granted by the shareholders in the Extraordinary General Meeting (EGM) on 8 April 2021. Lucenxia ceased to be a subsidiary of the Company with the completion took place on 3 May 2021.

#### 11. CHANGES IN COMPOSITION OF THE GROUP

- On 20 April 2021, the directors of the Company has approved the transfer of 100% equity shareholding of Lucenxia International Sdn. Bhd owned by Adventa Berhad to Mr. Low Chin Guan as part of compliance to the terms as set out in the SSA of the Proposed Disposal of Lucenxia.
- On 3 May 2021, Lucenxia (M) Sdn. Bhd. ceased to be the subsidiary of the Company.

#### 12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

#### 13. CAPITAL COMMITMENTS

There were no commitments for the purchase of property, plant and equipment at the financial period ended 30 September 2021.



# (Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

#### UNAUDITED NOTES TO FINANCIAL STATEMENTS

 $PART\ B$  – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

#### 14. PERFORMANCE REVIEW

	Individual Quarter Ended 3Q 2021	Individual Quarter Ended 3Q 2020	Changes	
	RM ('000)	RM ('000)	RM ('000)	% change
Revenue	43,423	14,466	28,957	207%
Profit before tax / (Loss before tax )	3,512	(5,227)	8,739	167%

Sales revenue improved by 207% over 2020 third quarter, with a strong contribution from PPE products.

Profit before tax is RM3.5m compared to a previous loss of RM 5.2 m.

#### 15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Reporting Quarter 3Q 2021	Previous Quarter 2Q 2021	Changes	Changes
	RM ('000)	RM ('000)	RM ('000)	%
Revenue	43,423	20,063	23,360	116%
Profit Before Tax (PBT)	3,512	7,728*	(4,216)	-54%
PBT excluding gain on subsidiary disposal	3,512	506	3,006	594%

<sup>\*</sup>Included in PBT of Q2 FY2021 is a gain on disposal of Lucenxia (M) Sdn. Bhd. ("Lucenxia Disposal") of RM7.2m.

Revenue in third quarter increased from RM20m to RM43m, an improvement of 116%. The Group's PBT excluding gain on disposal of subsidiary improved from RM0.5m to RM3.5m.



# (Company No : 200301016113 (618533-M)) (Incorporated in Malaysia)

# THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

#### UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### 16. COMMENTARY ON CURRENT YEAR PROSPECTS

The Company achieved a strong improvement from year 2020 and past quarters, in both top and bottom line. As the country like other global economies move into the COVID-19 endemic stage demand for healthcare products remain robust in hospitals and community care. As the year goes into the last quarter, typically an inventory management period by users, consumption is expected to moderate.

Margin in the current quarter was subdued by high ship freight cost that increased over 200% due to the global logistics bottleneck. The company has increased inventory as a prudent action to avoid a potential shipping crunch.

Barring any major pandemic related disruptions in the last months to the end of the year, the Company expect the year to end with a significant improvement over the previous year's results.

#### 17. UTILISATION OF PROCEEDS

The gross proceeds arising from Lucenxia (M) Sdn Bhd ("Lucenxia") Disposal of RM11 million are as follow.

Details of utilisation	Revised Expected utilization time frame	Proposed Utilisation	Amount Utilised	Balance unutilised	*Variation
		RM'000	RM'000	RM'000	RM'000
Working	Within	8,400	8,400	-	2,000
capital	24 months				
Business	Within	2,000	2,000	-	(2,000)
expansion	24 months				
Estimated	Within	600	600	-	-
expenses	3 months				
Total		11,000	11,000	-	-

<sup>\*</sup>Announcement on variation to the utilization of consideration from Lucenxia Disposal was made to Bursa Malaysia on 5 July 2021.

#### 18. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia)

# THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

#### UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### 19. TAXATION

The effective tax rate is lower than the statutory rate due to availability of tax losses brought forward to set off against taxable profits.

	Individual Quarter Ended		Cumulative Quarter Ended	
	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20
	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Income tax	803	-	803	-
Deferred tax assets/(liabilities)	-	-	-	-
Total	803	-	803	-

### 20. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

#### 21. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.

#### 22. CORPORATE PROPOSALS

There was no corporate proposal announced which remain uncompleted at the financial period ended 30 September 2021.

#### 23. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as of financial year ended 30 September 2021 as below.

	As at 30-Sep-21 RM ('000)	As at 30-Sep-20 RM ('000)
Current (Secured):		
Trade loan	6,053	-
Term Loan	-	2,000
	6,053	2,000
Non-Current (Secured):		
Term Loan	-	-
Total Bank Borrowings	6,053	2,000



# (Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

# UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### 24. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

#### 25. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

#### a. **Basic**

	Individual Quarter Ended		Cumulativ End	ve Quarter ded
	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20
Profit attributable to ordinary equity holders of the parent (RM '000)	2,529	(5,158)	9,118	(2,460)
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	1.66	(3.38)	5.97	(1.61)

#### b. Diluted

There were no diluted earnings per share.

#### 26. (LOSS) / PROFIT BEFORE TAX

(Loss) / profit before tax is stated after charging/(crediting):

	Individual Quarter Ended				-
	30-Sep-21 30-Sep-20		30-Sep-21	30-Sep-20	
	RM'000	RM'000	RM'000	RM'000	
Other income	(50)	(9)	(105)	(50)	
Interest income	(38)	(263)	(75)	(422)	
Net foreign exchange loss/(gain)	120	92	201	247	
Interest expenses	353	334	983	962	



(Company No : 200301016113 (618533-M)) (Incorporated in Malaysia) THIRD QUARTER REPORT ENDED 30 SEPTEMBER 2021

# UNAUDITED NOTES TO FINANCIAL STATEMENTS

#### 27. REALISED AND UNREALISED PROFITS/(LOSSES)

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is presented as follows:

	As at 30-Sep-2021	As at 30-Sep-2020
Group's total (Accumulated losses)/Retained profits:	RM'000	RM'000
Realised	(35,185)	(18,946)
Unrealised	(8,987)	(11,917)
Total Realised and unrealised	(44,172)	(30,863)
Less: Consol adjustments	50,763	37,655
(Accumulated losses) / Retained profits	6.591	6,792

#### 28. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 24<sup>th</sup> November 2021.

By Order of the Board Adventa Berhad CHUA SIEW CHUAN Company Secretary MAICSA 0777689